



## Repair Therapeutics Announces Pricing of Upsized Initial Public Offering

June 18, 2020

CAMBRIDGE, Mass. & MONTRÉAL--(BUSINESS WIRE)--Jun. 18, 2020-- Repair Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of its upsized initial public offering of 11,000,000 of its common shares at a public offering price of \$20.00 per share. The gross proceeds to Repair, before deducting underwriting commissions and offering expenses, are expected to be approximately \$220.0 million. All of the common shares are being offered by Repair. In addition, Repair has granted the underwriters a 30-day option to purchase up to 1,650,000 additional common shares at the initial public offering price, less the underwriting commissions.

Repair's common shares are expected to begin trading on the Nasdaq Global Select Market on June 19, 2020 under the ticker symbol "RPTX." The offering is expected to close on June 23, 2020, subject to customary closing conditions.

Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and Piper Sandler & Co. are acting as joint book-running managers for the offering.

A registration statement relating to the common shares being sold in this offering has been filed with the U.S. Securities and Exchange Commission and was declared effective on June 18, 2020. The offering of these shares is being made only by means of a prospectus forming part of the effective registration statement relating to these shares. Copies of the final prospectus, when available, may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone: 1-866-471-2526 or by emailing [prospectus-ny@ny.email.gs.com](mailto:prospectus-ny@ny.email.gs.com); Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at [PostSaleManualRequests@broadridge.com](mailto:PostSaleManualRequests@broadridge.com) or by telephone at (833) 297-2926; or Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at 800-747-3924 or by email at [prospectus@psc.com](mailto:prospectus@psc.com).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Repair's common shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

### About Repair Therapeutics

Repair Therapeutics is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs.

### Forward-Looking Statements

This press release includes certain disclosures that contain "forward-looking statements," including, without limitation, statements regarding Repair's expectations regarding the commencement of trading of its shares on the Nasdaq Global Select Market, the completion and timing of the closing of offering and the anticipated use of net proceeds from the offering. Forward-looking statements are based on Repair's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions and the completion of the offering, and the risks inherent in biopharmaceutical product development and clinical trials. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the final prospectus related to the offering to be filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Repair undertakes no duty to update such information except as required under applicable law.



View source version on [businesswire.com](https://www.businesswire.com/news/home/20200618005981/en/): <https://www.businesswire.com/news/home/20200618005981/en/>

### Repair:

Steve Forte  
Chief Financial Officer  
Repair Therapeutics Inc.  
[info@reparerx.com](mailto:info@reparerx.com)

### Investors:

Kimberly Minarovich  
Argot Partners  
[repair@argotpartners.com](mailto:repair@argotpartners.com)

### Media:

David Rosen  
Argot Partners  
212-600-1902  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)

Source: Repair Therapeutics Inc.